SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Crypto is trending as its dedicated community fervently champions the "OG meme" narrative of Rage Comics, positioning it as a "foundational meme reset" for the current market cycle. This active base expresses strong conviction, building an ecosystem with platforms like RageMaker and RageGames, and urging enthusiasts to "Return to the Memes" and "Rage On" to reclaim leadership in the meme coin space.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is drawing intense attention amid a controversial $200 million equity investment in Mr. Beast's company and a critical shareholder vote on authorizing 50 billion new shares. The community is fiercely divided, questioning if these strategic shifts represent a visionary pivot or a significant departure from its core Ethereum treasury focus, fueling concerns about dilution and management's priorities.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is currently trending as its CEO delivered a bullish presentation at a major healthcare conference, underscoring robust Miplyffa patient enrollment and an anticipated patent extension. This positive outlook, combined with a recent CFO departure and the appointment of a new board member with M&A experience, is fueling strong community speculation about a potential acquisition, even amidst discussions around a recent legal judgment against the company.

Springview Holdings Ltd. engages in the design and construction of residential and commercial buildings. It involves new construction, reconstruction, alterations, and other general contracting services. The company was founded in 2002 and is headquartered in Singapore.

Springview Holdings Ltd - Ordinary Shares - Class A

Springview Holdings Ltd

Springview Holdings Ltd (SPHL) is experiencing a parabolic surge, driven by news of its strategic partnership with Jiangsu GSO New Energy to develop solar-ready homes and green microgrids in Singapore. This, combined with its ultra-low float, has fueled intense community discussion around massive gains and short-squeeze potential, drawing comparisons to other highly volatile microcap runners.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is generating significant buzz due to a rumored major collaboration with POL and a recent integration with ACH, which the community views as a meaningful expansion of its utility. Many investors are anticipating that this "OG privacy coin" will follow the strong upward movement seen in Zcash amidst a broader resurgence of interest in the privacy token sector. Traders are actively discussing its potential to break key resistance levels and capitalize on its scarce supply for substantial upside.

Moolec Science SA engages in the development and production of science-based food ingredients. Its products include pet food, animal feed, and dietary supplements. The company was founded by Gastón Paladini, Henk Hoogenkamp, and Martin Salinas in 2020 and is headquartered in George Town, Cayman Islands.

Moolec Science SA

Moolec Science (MLEC) is trending following its recent 1-for-15 reverse stock split, which has drastically reduced its publicly traded float and ignited widespread community speculation about a potential short squeeze. Traders are actively drawing comparisons to other low-float stocks that have recently seen significant runs, anticipating high volatility driven by the tightened share structure and ongoing discussions around Nasdaq compliance. The stock's dramatic price action and the potential for a squeeze are key talking points among investors.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is attracting significant attention for its advanced GaN and SiC power solutions, which are crucial for high-efficiency architectures in next-generation AI data centers, including NVIDIA's 800-volt ecosystem. The community is highly engaged, anticipating potential contract announcements and a significant short squeeze, fueled by substantial short interest, as the company repositions for AI-driven growth.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is highly discussed following significant capital raises, including a $3 billion convertible preferred equity placement led by Apollo and a common stock offering, which are seen as pivotal for future acquisitions. The community is buzzing about CEO Brad Jacobs' proven 'playbook' for aggressive M&A in the building products distribution sector, with many viewing these moves as strategic funding for multiple large deals despite some short-term dilution concerns.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as the market grapples with the Senate's indefinite delay of key crypto legislation. Community discussion centers on whether this regulatory setback truly justifies the stock's sharp decline, with many perceiving it as market manipulation given Robinhood's expanding prediction market offerings and other growth initiatives. Investors are now closely watching crucial support levels for potential buying opportunities, amidst frustration over the stock's performance.

Macy's, Inc. engages in the retail of apparel, accessories, cosmetics, home furnishings, and other consumer goods. The firm's brands include Macy's, Bloomingdale's, and Bluemercury. It offers men's, women's, and children's apparel, women's accessories, intimate apparel, shoes, cosmetics, fragrances, as well as home and miscellaneous products. The company was founded by Rowland H. Macy in 1858 and is headquartered in New York, NY.

Macy`s Inc

Macy's Inc

Macy's is trending following a significant Q2 earnings beat and raised full-year guidance, signaling that its "Bold New Chapter" turnaround strategy is showing promising comparable sales growth, especially within its luxury segments. Community discussions are active, debating the sustainability of this retail revival, the stock's undervalued real estate assets in light of potential buyout interest, and the implications of management's cautious holiday spending outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Tilray’s Q2 revenue rose 3% to $217.5 million, beating estimates of $211.5 million, according to Fiscal.ai data</li><li>The management reaffirmed its fiscal 2026 adjusted EBITDA outlook of $62 million to $72 million.</li><li>Tilray is currently operating at an annualized run rate of about $150 million, CEO Irwin D. Simon told analysts on a call on Thursday.</li></ul>Tilray Brands (TLRY) stock gave up most of its early gains to trade about 2.5% higher on Friday after Alliance Global slashed its price target on the stock, pointing to limited visibility into the company’s long-term sales trajectory and cash flow following its second-quarter (Q2) fiscal 2026 results.Analyst Aaron Grey reduced Tilray’s target price to $10 from $20 while maintaining a ‘Neutral’ rating. He said the quarter came in largely in line at the consolidated level, with “some strengths offsetting some weaknesses,” but the firm stayed on the sidelines, looking for clearer insight into the company’s sales and cash flow outlook.<h2 class="st-heading-2">Q2 Print</h2>Tilray’s second-quarter (Q2) revenue rose 3% to $217.5 million, beating estimates of $211.5 million, according to Fiscal.ai data. The revenue increase was driven by a 36% jump in international medical cannabis sales. Net loss narrowed to $43.5 million from $85.3 million a year earlier.Operating cash flow remained negative, though it narrowed to $8.5 million compared to $40.7 million last year. The firm’s management reaffirmed its fiscal 2026 adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) outlook of $62 million to $72 million, citing long-term opportunities tied to U.S. cannabis rescheduling and medical expansion.Chairman and CEO Irwin D. Simon told analysts on a call on Thursday that Tilray is currently operating at an annualized run rate of about $150 million, driven mainly by international markets. Simon also added that Europe, particularly Germany, the U.K., and Poland, represents a significant growth opportunity.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday gains, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/TLRY">TLRY</a> remained in the ‘bearish’ territory over the past 24 hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/TLRY_jpg_463814541d.webp" alt="TLRY.jpg" width="922" height="96"><figcaption>&nbsp;</figcaption></figure>However, some users were bullish, with one highlighting Tilray’s strong results.<stembedurl>https://stocktwits.com/Mlitton13/message/641317326</stembedurl>The stock has declined 24% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-oklo-stock-surged-premarket-today-meta-deal/cmU2fX3R4dI">OKLO Stock Surged 20% In Premarket Today – What’s The Meta Agreement About?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Tilray Brands logo is seen displayed on a smartphone and in the background.

TLRY Stock In Focus After Alliance Global Halves Price Target

Alliance Global cut TLRY’s target price to $10 from $20, citing limited visibility into the company’s long-term sales trajectory and cash flow.

Equity

Cannabis ETFs Soar Double-Digits on Friday: Here's Why

Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.

Cannabis plants grow in the greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. (Photo by Drew Angerer/Getty Images)

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry?

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

<ul class="summary-bullets"><li>Bloomberg reported that the Centers for Medicare &amp; Medicaid Services (CMS), which runs the Medicare program, is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;</li><li>MSOS and YOLO, two key cannabis sector-focused funds, gained 3.4% and 2.7%, respectively.</li><li>The Trump administration seems to be backing cannabis as an industry, following its previous comments regarding CBD and reclassifying marijuana.</li></ul>Cannabis&nbsp;stocks advanced on Wednesday following a report speculating that certain U.S Medicare patients could soon be eligible to receive coverage for CBD under a new initiative.CBD, or cannabidiol, is a compound found in cannabis and used to treat sleep disorders, anxiety, pain, and inflammation. Some research suggests it may also treat cancer symptoms. The drug is sold as gummies, pet treats, and skincare supplements.<h2 class="st-heading-2">Cannabis Stocks Rally</h2>Tilray Brands’ shares rose 4.8%, while the over-the-counter stocks of Curaleaf Holdings, Trulieve Cannabis, and Green Thumb Industries gained between 2% to 5.6%. Shares of Innovative Industrial Properties, a real estate investment trust (REIT) that buys and leases specialized cannabis cultivation facilities, rose 1.1%.On Stocktwits, the retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/TLRY">TLRY</a> shifted to ‘extremely bullish’ from ‘bullish,’ while that for&nbsp;<a href="https://stocktwits.com/symbol/CURLF">CURLF</a> shifted to ‘bullish’ from ‘neutral.’ The sentiment was ‘bullish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">GTBIF</a>, and ‘bearish’ for&nbsp;<a href="https://stocktwits.com/symbol/GTBIF">TCNNF</a> and&nbsp;<a href="https://stocktwits.com/symbol/IIPR">IIPR</a> as of the last reading.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/MSOS">AdvisorShares Pure US Cannabis ETF (MSOS)</a>, which tracks U.S. cannabis companies exclusively, and the&nbsp;<a href="https://stocktwits.com/symbol/YOLO">AdvisorShares Pure Cannabis ETF (YOLO)</a>, which also tracks overseas companies and cannabis-adjacent businesses, rose 3.4% and 2.7%, respectively.<h2 class="st-heading-2">CMS Initaitive</h2>The rally came after Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-11-26/medicare-to-test-making-cbd-treatment-available-for-seniors">reported</a> that the Centers for Medicare &amp; Medicaid Services (CMS) is planning an initiative that would make some U.S. Medicare patients eligible for CBD coverage.&nbsp;Details of the proposed program aren’t available, but an early version of the plan focused on seniors in oncology and palliative care settings, according to a summary viewed by the news agency.Unnamed sources told Bloomberg that Howard Kessler, a payments financier who has advocated for expanded CBD access, met with Health and Human Services Secretary Robert F. Kennedy Jr. about the issue last month<h2 class="st-heading-2">A Trump Boost?</h2>The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. Hemp-derived cannabidiol (CBD) could "revolutionize senior healthcare" by slowing disease progression and serving as an alternative to prescription drugs, Trump had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-cannabis-stocks-lose-high-premarket-after-surge-triggered-by-trumps-post/chDDTJ9R3BB">said</a> in a video post in September.The previous month, Trump said his administration was weighing a move to reclassify marijuana as a less dangerous drug under federal law.That said, doubts over cannabis efficacy in healthcare remain. A&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2836267">recent study</a> funded by the Food and Drug Administration suggested that prolonged use of CBD may cause liver toxicity, while other research suggests it can interfere with other medications, harm male reproductive health, and pose potential risks to children and pregnant women.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/holiday-shopping-could-soar-to-a-record-1-trillion-this-year-with-online-spending-blasting-to-new-highs/cL5eLqVREW6">Holiday Shopping Could Soar To A Record $1 Trillion This Year, With Online Spending Blasting To New Highs</a>

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

The Zacks Analyst Blog Highlights MSOS, CNBS, WEED, MJ and YOLO

Zacks Analyst Blog highlights MSOS, CNBS, WEED, MJ, and YOLO as marijuana ETFs soar over 100% in three months on U.S. legalization hopes and investor optimism.

From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects 

Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism. 

Top-Performing ETFs of Last Week

ETFs tied to cannabis, Ethereum and Chinese tech stocks topped last week's winners list. Top performers were KSTR, YOLO, ARKZ, CHIQ and CNXT.

Cannabis ETFs Soar as Trump Mulls Over Marijuana Reclassification

Cannabis ETFs like WEED, CNBS and MJ surge after Trump confirmed that his administration is weighing marijuana's move from Schedule I to Schedule III.


Nasdaq-listed shares of Canopy Growth Corp. (CGC) fell 12% in pre-market trading on Friday after the cannabis company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.canopygrowth.com/investors/news-releases/canopy-growth-reports-fourth-quarter-and-fiscal-year-2025-financial-results/">reported</a> wider-than-expected fourth-quarter (Q4) loss.The company’s fourth quarter revenue fell 11% year-on-year (YoY) to C$65.03 million ($47.16 million), below an analyst estimate of C$70.87 million, according to Finchat data.The company attributed the drop to a decline in net revenue from its international markets cannabis, and Storz &amp; Bickel segments.In Canada, cannabis net revenue was C$40 million in the quarter, marking an increase of 4% YoY. However, across international markets, the revenue declined 35% YoY to C$8 million, owing to a decline in medical cannabis sales in Poland and Australia, the company said.Storz and Bickel, meanwhile, delivered net revenue of C$17 million in the quarter, a decrease of 23% YoY, owing to softer consumer demand for its devices. Storz and Bickel designs vaporizers for combustion-free vaporization and inhalation of dry herbs.The company’s gross margin fell by 500 basis points to 16% in the quarter, and it reported an adjusted loss before interest, taxes, depreciation, and amortisation (EBITDA) of C$9 million. Analysts had only expected a loss of C$3.13 million.The company’s total debt, however, decreased to C$304 million as of March 31, compared to C$597 million on the corresponding date of 2024.The company said on Friday that it plans to continue to focus on accelerating growth in global medical cannabis, improving commercial execution, and profitability in Canada’s adult-use cannabis market. The company also said that cost actions are underway and it expects annualized savings of at least C$20 million over the next 12 to 18 months.CFO Judy Hong also said that the company is committed to achieving positive adjusted EBITDA in the “near-term,” without specifying a timeline.On Stocktwits, retail sentiment around Canopy Growth stayed within the ‘bearish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_8_59_37_AM_png_cf8cb9e0cf.webp" alt="CGC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on May 30, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>CGC's Sentiment Meter and Message Volume as of 8:15 a.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user termed the Q4 earnings reports “a pretty big let down.” &nbsp;<stembedurl>https://stocktwits.com/JustAGlitchBTMFD/message/616291899</stembedurl><a href="https://stocktwits.com/symbol/CGC">CGC stock </a>is down by about 41% this year and by about 80% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/zymeworks-drug-gets-conditional-approval-for-biliary-tract-cancer-in-china/ch0Mun4RbMx">Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: I Canadian Dollar= 0.73 US Dollar)

A cart full of bagged marijuana is rolled through the corridors at the Canopy Growth Corporation headquarters in Smiths Falls, Ontario, on May 15, 2019. (Photo by Lane Turner/The Boston Globe via Getty Images)

Canopy Growth Stock Drops Pre-Market After Disappointing Q4 Earnings: Retail Terms It ‘A Pretty Big Let Down’

CFO Judy Hong said the company is committed to achieving positive adjusted EBITDA in the “near-term,” without specifying a timeline.

This REIT ETF Just Hit a 52-Week Low. Here’s Why It’s Time to Buy.

Twenty-two ETFs hit 52-week highs, and 17 hit 52-week lows on Tuesday. One of the ETFs hitting a 52-week low was an Invesco REIT that’s worth considering for income-focused investors. Here’s why.

Advisorshares Trust - AdvisorShares Pure Cannabis ETF

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

YOLO
AdvisorShares Pure Cannabis ETF

Feed

News

Sentiment

Fundamentals

Info

Latest YOLO News

YOLOAdvisorShares Pure Cannabis ETF